Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)
Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –
Niagen Bioscience price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Niagen Bioscience's price to sales ratio was 1.3× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 1.2× to 10.5×, with a median of 2.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.3× | −2.8 |
| 2025 | Dec 31, 2025 | 4.1× | −0.3 |
| 2024 | Dec 31, 2024 | 4.4× | +3.1 |
| 2023 | Dec 29, 2023 | 1.3× | −0.4 |
| 2022 | Dec 30, 2022 | 1.7× | −2.2 |
| 2021 | Dec 31, 2021 | 3.9× | +3.9 |
| 2020 | Dec 31, 2020 | 0.0× | −0.0 |
| 2019 | Dec 31, 2019 | 0.0× | −0.0 |
| 2018 | Dec 31, 2018 | 0.0× | −12.9 |
| 2017 | Dec 29, 2017 | 12.9× | +6.0 |
| 2016 | Dec 30, 2016 | 6.9× | −1.5 |
| 2015 | Dec 31, 2015 | 8.5× | −0.6 |
| 2014 | Dec 31, 2014 | 9.1× | −3.0 |
| 2013 | Dec 31, 2013 | 12.1× | +7.2 |
| 2012 | Dec 31, 2012 | 4.9× | +0.1 |
| 2011 | Dec 30, 2011 | 4.8× | – |
See a number that looks wrong?